Research Papers:
Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1864 views | HTML 2970 views | ?
Abstract
Cenny Taslim1, Daniel Y. Weng1, Theodore M. Brasky1, Ramona G. Dumitrescu2, Kun Huang1, Bhaskar V.S. Kallakury3, Shiva Krishnan1, Adana A. Llanos4, Catalin Marian1,11, Joseph McElroy5, Sallie S. Schneider6, Scott L. Spear7, Melissa A. Troester8, Jo L. Freudenheim9, Susan Geyer10, Peter G. Shields1
1Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
2Distilled Spirits Council of the United States, Washington, DC, USA
3Department of Pathology, Georgetown University, Washington, DC, USA
4Department of Epidemiology, Rutgers University, New Brunswick, NJ, USA
5Center for Biostatistics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
6Pioneer Valley Life Sciences Institute, Springfield, MA, USA
7Department of Plastic Surgery, Georgetown University Hospital, Washington, DC, USA
8Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
9Departement of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA
10Health Informatics Institute, University of South Florida, Tampa, FL, USA
11Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Correspondence to:
Peter G. Shields, email: [email protected]
Keywords: microRNA, epigenetics, breast cancer risk prediction, tissue-based biomarkers, healthy women
Received: September 07, 2016 Accepted: October 22, 2016 Published: November 09, 2016
ABSTRACT
Background: Genome-wide miRNA expression may be useful for predicting breast cancer risk and/or for the early detection of breast cancer.
Results: A 41-miRNA model distinguished breast cancer risk in the discovery study (accuracy of 83.3%), which was replicated in the independent study (accuracy = 63.4%, P=0.09). Among the 41 miRNA, 20 miRNAs were detectable in serum, and predicted breast cancer occurrence within 18 months of blood draw (accuracy 53%, P=0.06). These risk-related miRNAs were enriched for HER-2 and estrogen-dependent breast cancer signaling.
Materials and Methods: MiRNAs were assessed in two cross-sectional studies of women without breast cancer and a nested case-control study of breast cancer. Using breast tissues, a multivariate analysis was used to model women with high and low breast cancer risk (based upon Gail risk model) in a discovery study of women without breast cancer (n=90), and applied to an independent replication study (n=71). The model was then assessed using serum samples from the nested case-control study (n=410).
Conclusions: Studying breast tissues of women without breast cancer revealed miRNAs correlated with breast cancer risk, which were then found to be altered in the serum of women who later developed breast cancer. These results serve as proof-of-principle that miRNAs in women without breast cancer may be useful for predicting breast cancer risk and/or as an adjunct for breast cancer early detection. The miRNAs identified herein may be involved in breast carcinogenic pathways because they were first identified in the breast tissues of healthy women.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13241